Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424697 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00424697 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 26 participants.
The verdict
NCT00424697, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Data suggests that imaging activity of the brain can measure the effects of anti-anxiety drugs. This study will investigate the effect of GW876008 on areas of the brain involved with thinking and emotion
Interventions
- DRUG placebo
- DRUG lorazepam
- DRUG GW876008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424697
The ClinicalTrials.gov registry entry for NCT00424697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00424697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00424697 about?
NCT00424697 is a clinical study titled "A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.". Data suggests that imaging activity of the brain can measure the effects of anti-anxiety drugs. This study will investigate the effect of GW876008 on areas of the brain involved with thinking and emotion
What is the current status of trial NCT00424697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2007-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00424697?
The interventions under investigation include: placebo (DRUG), lorazepam (DRUG), GW876008 (DRUG).
Who is sponsoring clinical trial NCT00424697?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.